多巴胺抑制了心力衰竭患者的每分钟通风
P van de Borne1, R Oren, V K Somers
1Department of Internal Medicine and the Cardiovascular Center, University of Iowa Hospitals and Clinics, Iowa City, USA.
Circulation
|July 29, 1998
概括
低剂量的多巴胺会损害身体对健康个体低氧的反应,并且可以减少心力衰竭患者的呼吸. 这种影响可能会对缺氧患者,特别是心力衰竭患者的结果产生负面影响.
科学领域:
- 心血管生理学心血管生理学
- 关键护理医学 关键护理医学
- 呼吸系统生理学 呼吸系统生理学
背景情况:
- 低剂量的多巴胺通常在重症监护机构中使用.
- 多巴胺的使用可能会通过抑制化学受体 afferents 来降低化学反射对缺氧的敏感性.
研究的目的:
- 为了研究低剂量多巴胺在正常氧和缺氧期间对健康受试者的心肺呼吸反应的影响.
- 检查多巴胺对严重心力衰竭患者通风的影响.
主要方法:
- 在10名健康的年轻人中进行了一项双盲随机交叉研究.
- 测量包括氧和度,分钟通风和在正常和缺氧期间的同情神经活动.
- 在8名患有严重心力衰竭的患者和8名年龄匹配的对照人群中,对多巴胺的呼吸系统反应也进行了评估.
主要成果:
- 在健康人群中,多巴胺在正常氧气期间没有改变分钟通风,但在缺氧期间减少了 (12.9对15.8L/分钟).
- 与安慰剂 (84%) 相比,多巴胺 (78%) 的 hypoxic 氧和率较低.
- 多巴胺抑制了心力衰竭患者的通风,但不是对照组,随之而来的氧和度下降和PETCO2的增加.
结论:
- 低剂量的多巴胺抑制了人类对缺氧的化学反射反应,主要影响了对同情活动的通风.
- 多巴胺还抑制了normoxic心力衰竭患者的通风.
- 多巴胺引起的呼吸道抑制可能会使缺氧患者的结果恶化,特别是心力衰竭患者.
更多相关视频
07:09Assessment of Pulmonary Capillary Blood Volume, Membrane Diffusing Capacity, and Intrapulmonary Arteriovenous Anastomoses During Exercise
Published on: February 20, 2017
04:20Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Hyperpnea and Hyperventilation
Hyperventilation refers to a higher-than-normal rate and depth of breathing, often associated with anxiety attacks. This excessive breathing surpasses the body's need to expel CO2, leading to a condition known as hypocapnia - an unusually low level of carbon dioxide in the blood. Hypocapnia can constrict cerebral blood vessels, reducing blood flow to the brain, which may result in dizziness or fainting. Early signs include tingling and muscle spasms in the hands and face, caused by falling...
01:21Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...